Compare Match Group Inc (MTCH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Novo Nordisk A/S — how do they compare? Match Group Inc trades at $39.02 (market cap $9.10B), while Novo Nordisk A/S trades at $49.36 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 24.2× Match Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MTCH | NVO | |
|---|---|---|
Market Cap | $9.10B | $220.53B |
Sector | Media | Health |
52-Week High | $40.29 | $71.70 |
52-Week Low | $28.90 | $35.29 |
Enterprise Value | $12.05B | $239.49B |
Dividend Yield | 2.05% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $38.75, down 1.02% today, near the analyst low target of $38.00. The stock shows a bullish technical signal with strong moving average support, while oscillators remain neutral. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Revenue growth is stable at $3.5B annually, with net income margins improving to 17.59% in 2025. Positive news highlights Tinder's turnaround efforts and Hinge's growth, with a dividend scheduled for July 2026.
Outlook is cautiously optimistic with a consensus price target of $41.63, implying ~7% upside. Strengths include high gross margins (73.8%) and consistent cash flow growth. Risks involve high debt ($3.85B) and Tinder's user declines offset by pricing. Analyst sentiment is bullish (53% Buy), but execution on user engagement remains critical for sustained gains.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
